Abstract
Specimens of formalin-fixed, paraffin-embedded non-small-cell lung carcinomas (NSCLCs; n = 187) were analysed immunohistochemically for expression of cyclin A. The analysis was intended to determine whether cyclin A has additional prognostic value for predicting patients' survival and drug response. Of the 187 NSCLCs, 141 cases (75%) showed expression of cyclin A. Patients with cyclin A-positive carcinomas had significantly shorter median survival times than patients with cyclin A-negative carcinomas (79 vs 129 weeks, P = 0.045). Similar results were obtained with more homogeneous groups of patients: patients with only T3 tumours, patients with epidermoid carcinomas and patients with lymph node involvement. The clinical parameters (age, stage, histology, extent of tumour size, lymph node involvement) had no influence on expression of cyclin A. A direct correlation between cyclin A and the proportion of S-phase cells (P = 0.08) and an inverse relationship between cyclin A and the proportion of G0/G1-phase cells (P = 0.04) were found. Furthermore, a significant correlation between the expression of cyclin A and the response of NSCLC to doxorubicin in vitro was detected (P = 0.026).
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Abel U., Berger J., Wiebelt H. CRITLEVEL: an exploratory procedure for the evaluation of quantitative prognostic factors. Methods Inf Med. 1984 Jul;23(3):154–156. [PubMed] [Google Scholar]
- Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol. 1995 Sep;147(3):545–560. [PMC free article] [PubMed] [Google Scholar]
- Dutta A., Chandra R., Leiter L. M., Lester S. Cyclins as markers of tumor proliferation: immunocytochemical studies in breast cancer. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5386–5390. doi: 10.1073/pnas.92.12.5386. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hartsough M. T., Frey R. S., Zipfel P. A., Buard A., Cook S. J., McCormick F., Mulder K. M. Altered transforming growth factor signaling in epithelial cells when ras activation is blocked. J Biol Chem. 1996 Sep 13;271(37):22368–22375. doi: 10.1074/jbc.271.37.22368. [DOI] [PubMed] [Google Scholar]
- Inohara S., Kitano Y. Immunohistochemical detection of cyclin D and cyclin A in human hyperproliferative epidermis. Arch Dermatol Res. 1994;286(8):504–506. doi: 10.1007/BF00371580. [DOI] [PubMed] [Google Scholar]
- Paterlini P., Flejou J. F., De Mitri M. S., Pisi E., Franco D., Bréchot C. Structure and expression of the cyclin A gene in human primary liver cancer. Correlation with flow cytometric parameters. J Hepatol. 1995 Jul;23(1):47–52. doi: 10.1016/0168-8278(95)80310-6. [DOI] [PubMed] [Google Scholar]
- Volm M., Brüggemann A., Günther M., Kleine W., Pfleiderer A., Vogt-Schaden M. Prognostic relevance of ploidy, proliferation, and resistance-predictive tests in ovarian carcinoma. Cancer Res. 1985 Oct;45(10):5180–5185. [PubMed] [Google Scholar]
- Volm M., Hahn E. W., Mattern J., Müller T., Vogt-Moykopf I., Weber E. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res. 1988 May 15;48(10):2923–2928. [PubMed] [Google Scholar]
- Zindy F., Lamas E., Chenivesse X., Sobczak J., Wang J., Fesquet D., Henglein B., Bréchot C. Cyclin A is required in S phase in normal epithelial cells. Biochem Biophys Res Commun. 1992 Feb 14;182(3):1144–1154. doi: 10.1016/0006-291x(92)91851-g. [DOI] [PubMed] [Google Scholar]